China Shineway Pharmaceutical Group Limited (Shineway Pharma) announced that shareholders approved every item on the agenda at the Annual General Meeting (AGM) held on 28 May 2026. All resolutions were decided by poll, with Computershare Hong Kong Investor Services Limited acting as scrutineer.

The audited 2025 financial statements, directors’ report and independent auditor’s report received 99.67% of votes cast, signalling strong shareholder endorsement of the company’s past-year performance.

Board composition remains unchanged after the re-election of three directors: • Xin Yunxia re-elected with 97.66% support. • Li Huimin re-elected with 99.15% support. • Yew Yat On re-elected with 99.23% support.

Shareholders also authorised the board to set directors’ remuneration, backed by 99.97% of votes.

Deloitte Touche Tohmatsu was re-appointed as external auditor for another term, receiving 95.66% approval.

A general mandate permitting the board to allot and issue new shares up to 20% of issued capital—equivalent to approximately 0.17 billion shares based on the current 0.83 billion total—passed with 92.87% support.

All directors, except Yew Yat On due to other business commitments, attended the meeting in person or electronically. No shareholder was required to abstain, and no special voting restrictions were noted under the Hong Kong Listing Rules.